Application of immunotherapy combined with chemotherapy in neoadjuvant therapy of esophageal squamous cell carcinoma

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100044427

Enrollment

Unknown

Registered

2021-03-18

Start date

2021-05-01

Completion date

Unknown

Last updated

2021-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal squamous carcinoma

Interventions

intervention:Chemotherapy combined with immunotherapy

control group:Nil

Eligibility

Sex/Gender

All

Age

40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. T3-4 N0-N2 esophageal squamous cell carcinoma was first diagnosed, and no other treatment was performed. 2. Generally, it can tolerate chemotherapy and immunotherapy. 3. Family members understand and agree to chemotherapy combined with immunotherapy. 4. No distant transfer.

Exclusion criteria

Exclusion criteria: Nil

Design outcomes

Primary

Measure	Time frame
PFS;	—

Countries

China

Contacts

Public ContactCai haibo

Ji'ning First Hospital

shalazhang2@163.com+86 13518670801

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026